G1 Therapeutics Inc
NASDAQ:GTHX
G1 Therapeutics Inc
Revenue
G1 Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
G1 Therapeutics Inc
NASDAQ:GTHX
|
Revenue
$82.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
G1 Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
G1 Therapeutics Inc
Breakdown by Segments
G1 Therapeutics Inc
Total Revenue:
82.5m
USD
|
Product Sales, Net:
46.3m
USD
|
License Revenue:
36.2m
USD
|
See Also
What is G1 Therapeutics Inc's Revenue?
Revenue
82.5m
USD
Based on the financial report for Dec 31, 2023, G1 Therapeutics Inc's Revenue amounts to 82.5m USD.
What is G1 Therapeutics Inc's Revenue growth rate?
Revenue CAGR 3Y
22%
Over the last year, the Revenue growth was 61%. The average annual Revenue growth rates for G1 Therapeutics Inc have been 22% over the past three years .